Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease
Levodopa Induced Dyskinesia
About this trial
This is an interventional treatment trial for Levodopa Induced Dyskinesia focused on measuring Levetiracetam, Levodopa-induced dyskinesias, Parkinson's
Eligibility Criteria
Inclusion Criteria: Diagnosis of PD will be according to the criteria of United Kingdom Parkinson's Disease Society Brain Bank. Other inclusion criteria: Patients between ages 30 and 80 Hoehn and Yahr stage of PD over IIb Levodopa-induced dyskinesias (LID) despite optimization of antiparkinsonian medication LID severity 2 on item 32 and duration 2 on item 33 of the Unified Parkinson's Disease Rating Scale (UPDRS) part IV Patient is willing to adhere to protocol requirements as evidence by written informed consent Exclusion Criteria: Patient has a history of any medical condition or clinically significant laboratory abnormalities that can subject them to unwarranted risk. Female patient is pregnant or breastfeeding or has not been using or was not continuing to use an adequate contraceptive method for the last 30 days, or is not at least one year post-menopausal. Patient with ablative surgeries or DBS implantation electrodes for diseases of the basal ganglia. Patient has a low Mini-mental Examination MMSE score <25 or has a history of bipolar psychosis or schizophrenia. Patient is unwilling to sign an informed consent or to comply with protocol requirements. Patient is taking or has taken in the past month amantadine.
Sites / Locations
- Department of Neurology, 1st Hospital of Social Security Services
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Placebo Comparator
Active Comparator
Placebo Comparator
1
2
3
4
500mg levetiracetam for one week and 1000mg levetiracetam for one week
placebo
After crossover arm 3 equals arm 1
After crossover arm 4 equals arm 2